Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Mar 28, 2018 (9 years ago)

Conzerol zero molluscum contagiosum

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

cGMP Deviations

Cause type: cGMP deviation

Departures from current Good Manufacturing Practice found in production or during FDA inspection. A broad quality-system cause: the batch was made under conditions that fall short of FDA manufacturing standards. All cgmp deviation recalls.

What was recalled

Conzerol zero molluscum contagiosum, Topical Cream, Net weight 0.78 (22g), Elrose Labs, Sanford Fl 32771 USA --- NDC 70223-001-06

Affected NDC 70223-0001-06

Compare with the code on your package — it is the most precise check available.

Recalling firm
Elroselabs Inc.
NDC code
70223-001-06
Origin
FL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0621-2018 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other recalls by Elroselabs Inc.

All 2018 recalls
Class II · Moderate risk

Molleave

cGMP Deviations

Terminated cGMP deviation Elroselabs Inc. D-0622-2018

Other cgmp deviation recalls from 2018

All cgmp deviation recalls
Class II · Moderate risk

Oxygen

CGMP Deviations

Terminated cGMP deviation Roberts Home Medical LLC D-1002-2019
Class II · Moderate risk

Cidofovir Dihydrate

CGMP Deviations: Active Pharmaceutical Ingredient (API) manufacturer is on FDA Import Alert.

Terminated cGMP deviation LGM Pharma LLC D-0486-2019